Rubius Therapeutics, Inc. RUBY
We take great care to ensure that the data presented and summarized in this overview for Rubius Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in RUBY
Top Purchases
Top Sells
About RUBY
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at RUBY
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 24
2023
|
Dannielle Appelhans CEO and President |
SELL
Open market or private sale
|
Direct |
10,385
-100.0%
|
$0
$0.13 P/Share
|
|
Feb 01
2023
|
Dannielle Appelhans CEO and President |
SELL
Open market or private sale
|
Direct |
3,878
-27.19%
|
$0
$0.25 P/Share
|
|
Feb 01
2023
|
Pablo J Cagnoni Director |
SELL
Open market or private sale
|
Direct |
8,448
-11.34%
|
$0
$0.25 P/Share
|
|
Jan 31
2023
|
Dannielle Appelhans CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+34.46%
|
-
|
|
Jan 31
2023
|
Laurence A. Turka Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,593
-12.36%
|
$0
$0.24 P/Share
|
|
Jan 31
2023
|
Laurence A. Turka Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,625
+29.13%
|
-
|
|
Jan 31
2023
|
Pablo J Cagnoni Director |
SELL
Open market or private sale
|
Direct |
7,240
-8.85%
|
$0
$0.24 P/Share
|
|
Jan 31
2023
|
Pablo J Cagnoni Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+23.41%
|
-
|
|
Jan 29
2023
|
Laurence A. Turka Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,438
+37.57%
|
-
|
|
Jan 29
2023
|
Pablo J Cagnoni Director |
BUY
Exercise of conversion of derivative security
|
Direct |
21,250
+27.24%
|
-
|
|
Aug 10
2022
|
Dannielle Appelhans CEO and President |
SELL
Open market or private sale
|
Direct |
5,737
-45.9%
|
$0
$0.8 P/Share
|
|
Aug 09
2022
|
Dannielle Appelhans CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+50.0%
|
-
|
|
Apr 21
2022
|
David R Epstein Director |
BUY
Open market or private purchase
|
Direct |
30,000
+0.63%
|
$30,000
$1.44 P/Share
|
|
Feb 01
2022
|
Laurence A. Turka Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,517
-33.84%
|
$15,102
$6.57 P/Share
|
|
Feb 01
2022
|
Maiken Keson Brookes CLO & Corp. Secretary |
SELL
Open market or private sale
|
Direct |
2,732
-33.83%
|
$16,392
$6.57 P/Share
|
|
Feb 01
2022
|
Pablo J Cagnoni Director |
SELL
Open market or private sale
|
Direct |
6,730
-15.93%
|
$40,380
$6.57 P/Share
|
|
Jan 29
2022
|
Laurence A. Turka Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,438
+50.0%
|
-
|
|
Jan 29
2022
|
Maiken Keson Brookes CLO & Corp. Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
8,075
+50.0%
|
-
|
|
Jan 29
2022
|
Pablo J Cagnoni Director |
BUY
Exercise of conversion of derivative security
|
Direct |
21,250
+33.46%
|
-
|
|
Mar 19
2021
|
Flagship Ventures Fund Iv General Partner LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
210,000
+1.41%
|
$6,090,000
$29.0 P/Share
|